DrugLib.com — Drug Information Portal

Rx drug information, pharmaceutical research, clinical trials, news, and more


Nutrilib.com
A comprihensive source of nutritional information

Lamotrigine in the Treatment of Bipolar Disorder in Women of Reproductive Age

Information source: Stanford University
Information obtained from ClinicalTrials.gov on March 21, 2008
Link to the current ClinicalTrials.gov record.

Condition(s) targeted: Bipolar Disorder

Phase: N/A

Status: Recruiting

Sponsored by: Stanford University

Official(s) and/or principal investigator(s):
Natalie L Rasgon, M.D., Ph.D., Principal Investigator, Affiliation: Stanford University

Overall contact:
Margaret F Reynolds, B.A., Phone: (650) 725-2528, Email: mforbes@stanford.edu

Summary

This project will expand current knowledge of reproductive biology in women with bipolar disorder as well as assessing the impact of lamotrigine use for the treatment of bipolar disorder on reproductive function. Specifically, this study examines mood over the menstrual cycle and ovulation for three consecutive menstrual cycles in women treated for bipolar I, II, or NOS (not otherwise specified) with lamotrigine. In addition, testosterone and lipid concentrations will be measured before the participant starts receiving lamotrigine, as well as six months after receiving lamotrigine.

Clinical Details

Official title: Lamotrigine in the Treatment of Bipolar Disorder in Women of Reproductive Age

Study design: Natural History, Longitudinal, Defined Population, Prospective Study

Eligibility

Minimum age: 18 Years. Maximum age: 45 Years. Gender(s): Female.

Criteria:

Inclusion Criteria:

- Female

- Ages 18 through 45

- Diagnosis of bipolar disorder (I, II, or NOS)

- Willing to sign the Human Subject Protection Consent Form prior to enrollment into the

study

- Willing to use lamotrigine

- Never used lamotrigine prior to study entry

Exclusion Criteria:

- Unwilling or unable to comply with study requirements, e. g. complete forms, or attend

scheduled evaluations

- Significant alcohol and/or substance abuse or dependence within the prior 6 months

- Used lamotrigine prior to study entry, or currently using lamotrigine at study entry

Locations and Contacts

Margaret F Reynolds, B.A., Phone: (650) 725-2528, Email: mforbes@stanford.edu

Department of Psychiatry and Behavioral Sciences, Stanford University School of Medicine, Stanford, California 94305, United States; Recruiting
Pascale G Stemmle, B.S., Phone: 650-725-2528, Email: pascale@stanford.edu
Heather Kenna, M.A., Phone: (650) 724-0521, Email: hkenna@stanford.edu
Additional Information

Behavioral Neuroendocrinology Program website


Last updated: February 8, 2007

Page last updated: March 21, 2008

-- advertisement -- The American Red Cross

We comply with
HONcode standard.
Verify here.
Home | About Us | Contact Us | Site usage policy | Privacy policy

All Rights reserved - Copyright DrugLib.com, 2006-2008